Magnetic Fields: A New Weapon Against Deadly Implant Infections

DALLAS, TX – February 26, 2026 – In a significant step forward for orthopedic medicine, Dallas-based Solenic Medical has announced the publication of pivotal research that could revolutionize how doctors combat one of the most feared complications of surgery: implant-associated infections. The peer-reviewed study, published in the prestigious journal Scientific Reports, demonstrates that non-invasive alternating magnetic fields (AMF) can dramatically enhance the power of antibiotics against the stubborn bacterial shields known as biofilms.

For the millions of patients who rely on metallic implants like artificial knees, hips, and trauma plates, this development offers a ray of hope against infections that are notoriously difficult to treat, often requiring multiple painful and costly surgeries. The findings validate Solenic's innovative approach, which uses magnetic forces to disrupt these bacterial fortresses, making them vulnerable to standard drugs once again.

A Magnetic Solution to a Bacterial Siege

The core of the problem lies in biofilm, a slimy, matrix-like structure that bacteria build on surfaces, including medical implants. This protective layer makes the embedded bacteria hundreds or even thousands of times more resistant to both the body’s immune system and conventional antibiotics. It’s the reason why prosthetic joint infections (PJIs) can become chronic, recurrent, and devastatingly difficult to eradicate with medication alone.

Solenic Medical’s technology tackles this challenge head-on. The newly published research, titled “Alternating magnetic fields enhance anti-biofilm activity across pathogen and antibiotic space,” details how their AMF platform works. By exposing a metallic implant to a targeted magnetic field, the system generates localized heat through eddy currents on the implant's surface. This gentle heating is precisely enough to disrupt the biofilm’s structure without harming surrounding tissue, effectively lowering the bacteria's defenses.

The results are striking. The study showed that when combined with antibiotics, AMF treatment led to a massive reduction in biofilm. For Gram-positive pathogens, a common culprit in PJIs, the combination therapy achieved an average 5.72-log reduction—a term representing a kill rate of over 99.999%. The effect was similarly potent against Gram-negative organisms.

“This publication provides strong peer-reviewed validation of our AMF platform and its ability to enhance antibiotic activity against biofilms,” said Bart Bandy, Solenic Medical CEO, in a statement. “Biofilm-associated infections remain one of the most difficult challenges in orthopedic care, and these results support the potential of AMF to address a critical unmet need.”

Crucially, the study confirmed this synergistic effect works across a wide range of pathogens, including Staphylococcus aureus and Pseudomonas aeruginosa, as well as different classes of antibiotics and various types of implant metals. This broad applicability suggests the technology could become a versatile tool in the orthopedic arsenal.

“Seeing this consistent enhancement across multiple pathogens, antibiotics, and implant materials reinforces the potential of alternating magnetic fields as a broadly applicable adjunct to antimicrobial therapy,” noted Dr. David Greenberg, Chief Medical Officer and co-founder of Solenic Medical.

Beyond the Lab: A New Hope for Patients

The scientific breakthrough is significant, but its true impact is measured in human terms. Prosthetic joint infections are a growing crisis. According to the American Joint Replacement Registry's 2024 report, infection is the leading cause for knee revision surgeries (33.1%) and the most common reason for hip revisions (21.4%). With an aging population and the number of joint replacements projected to soar in the coming decade, the incidence of these infections is set to rise.

The current gold standard for treating a chronic PJI is often a grueling two-stage revision. This process involves surgically removing the infected implant, implanting a temporary antibiotic-laced spacer, administering weeks of high-dose intravenous antibiotics, and finally, performing a second major surgery to place a new permanent implant. The ordeal is physically and emotionally draining for patients and carries significant risks, with mortality rates for PJIs being comparable to some forms of cancer.

The economic burden is equally staggering. Treating a single PJI can cost tens of thousands of dollars, and the total projected cost in the U.S. was estimated to be over $1.6 billion in 2020. Solenic's technology offers a potential paradigm shift: a non-invasive, non-surgical treatment that works alongside existing antibiotics to clear an infection, potentially sparing patients from revision surgeries altogether.

From Concept to Clinic: Solenic's Strategic Ascent

Solenic Medical is not just a laboratory concept; it is a company on a clear trajectory toward clinical reality. The firm’s progress has been recognized by the U.S. Food and Drug Administration, which granted its AMF device a coveted Breakthrough Device Designation in 2020, signaling its potential to provide a more effective treatment for a debilitating condition and expediting its review process.

The company is already putting its technology to the test. In April 2025, Solenic successfully treated its first patient in an FDA-approved early feasibility clinical trial. This study is evaluating the safety of the SOLA-2 AMF Knee System in patients with suspected knee implant infections. This followed a successful compassionate use authorization in late 2025, where the technology was used as an adjunct to surgery for a patient with a serious PJI, with no device-related adverse events reported.

While other companies are exploring biofilm disruption, many approaches are minimally invasive or involve specialized antimicrobial coatings. For instance, Garwood Medical Devices' BioPrax technology, which also has FDA Breakthrough status, uses a mild electric current to disrupt biofilm but is described as minimally-invasive. Solenic’s approach stands out for being entirely non-contact and non-surgical, offering a short treatment that could be administered in an outpatient setting.

With a strong intellectual property portfolio originating from research at UT Southwestern Medical Center, successful preclinical and early human studies, and a clear regulatory path, Solenic Medical is methodically advancing its platform. The company is actively raising funds to support pivotal trials and expand the technology’s application to other implants, such as hips and trauma hardware, offering a new line of defense in the ongoing battle to make modern medical miracles safer for everyone.